Hypoxia-driven immune resistance to anti-PD-1/PD-L1 therapy: Mechanistic insights and therapeutic opportunities
{{output}}
Immune checkpoint blockade targeting programmed death protein-1 (PD-1) and its ligand PD-L1 has shown substantial therapeutic benefit in only a subset of patients with solid tumors, highlighting the urgent need to improve cancer immunotherapy outcomes. Hypoxia... ...
